Tumor patients are the high risk population of being infected by SARS-CoV-2 during the COVID-19 pandemic. In order to reduce the infection risk of the tumor patients and maintain effective antitumor treatment, the preventive strategy for tumor patients in stationary phase, in treatment period, in immunosuppressor treatment, with fever, and involved in clinical trials, are discussed here with consideration of the disease features of the tumor patients and the experience of pharmaceutical care. In addition, suggestions regarding daily protection, diet and follow-up strategy for the tumor patients are provided.